Figure 1From: Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using OmalizumabRush mOIT protocol timeline. Amount of maintenance dose depends on number of allergens dosed (4000 mg per allergen). *Double-blind, placebo-controlled food challenges (DBPCFCs).Back to article page